Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma

The monoclonal antibody zolbetuximab (formerly IMAB362), which is being developed as a potential treatment for gastric cancer (GC), targets Claudin 18.2 (CLDN18.2), a GC biomarker. This study aimed to determine the prevalence of CLDN18.2 in primary tumors and lymph node (LN) metastases of Japanese p...

Full description

Saved in:

Bibliographic Details
Published in:	Japanese journal of clinical oncology Vol. 49; no. 9; p. 870
Main Authors:	Rohde, Christoph, Yamaguchi, Rin, Mukhina, Svetlana, Sahin, Ugur, Itoh, Kyogo, Türeci, Özlem
Format:	Journal Article
Language:	English
Published:	England 01.09.2019
Subjects:	Adenocarcinoma - genetics Adenocarcinoma - metabolism Adenocarcinoma - pathology Antibodies, Monoclonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Asian Continental Ancestry Group Claudins - genetics Gene Expression Regulation, Neoplastic Humans Immunohistochemistry Lymphatic Metastasis - genetics Stomach Neoplasms - genetics Stomach Neoplasms - metabolism Stomach Neoplasms - pathology prevalence immunohistochemistry gastric cancer Claudin biomarkers
ISSN:	1465-3621, 1465-3621
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!